0000950170-24-062079.txt : 20240517 0000950170-24-062079.hdr.sgml : 20240517 20240517210652 ACCESSION NUMBER: 0000950170-24-062079 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240516 FILED AS OF DATE: 20240517 DATE AS OF CHANGE: 20240517 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Farwell Wildon CENTRAL INDEX KEY: 0001847941 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39509 FILM NUMBER: 24962176 MAIL ADDRESS: STREET 1: C/O DYNE THERAPEUTICS, INC. CITY: 830 WINTER STREET STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dyne Therapeutics, Inc. CENTRAL INDEX KEY: 0001818794 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364883909 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 786-8230 MAIL ADDRESS: STREET 1: 1560 TRAPELO ROAD CITY: WALTHAM STATE: MA ZIP: 02451 4 1 ownership.xml 4 X0508 4 2024-05-16 0001818794 Dyne Therapeutics, Inc. DYN 0001847941 Farwell Wildon 1560 TRAPELO ROAD WALTHAM MA 02451 false true false false Chief Medical Officer true Common Stock 2024-05-16 4 S false 1956 28.20 D 148604 D Common Stock 2024-05-16 4 S false 425 28.59 D 148179 D Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on November 15, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on January 25, 2024 and the sale does not represent a discretionary trade by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $28.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $28.51 to $28.70, inclusive. Includes 119,209 unvested RSUs. /s/ Richard Scalzo, Attorney-in-Fact 2024-05-17